Vetoquinol SA (VETO.PA) stock: key figures, P/E, revenue and dividend
Health Care · France · ISIN FR0004186856
Vetoquinol SA financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 539.00 m EUR | 525.00 m EUR |
| Gross profit | 387.00 m EUR | 160.00 m EUR |
| EBIT | 77.00 m EUR | 73.00 m EUR |
| Net income | 58.00 m EUR | 57.00 m EUR |
| Diluted EPS – continuing operations | 4.97 EUR | 4.79 EUR |
Full history since 2003, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Vetoquinol SA
Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA operates as a subsidiary of Soparfin SCA.
More stocks
- Basilea Pharmaceutica AG Allschwil (BSLN.SW)
- Morgan Stanley Direct Lending Fund (MSDL)
- Finework (Hu Nan) New Energy Technology Co. Ltd. (301232.SZ)
- Hunan Kaimeite Gases Co Ltd (002549.SZ)
- Hunan Valin Wire & Cable Co Ltd (001208.SZ)
- Shenzhen iN-Cube Automation Co. Ltd. (301312.SZ)
- Precision Drilling Corporation(Calgary) (PD.TO)
- QUINSTREET, INC (QNST)
- Dongwon Ind (006040.KS)
- Guangdong Xianglu Tungsten Co Ltd (002842.SZ)
- Inhibrx Biosciences, Inc. (INBX)
- H&K (MLHK.PA)
Not investment advice. All data without warranty, price as of 04.11.2026. Details in the risk notice.